Cala announced today that it received FDA clearance for its kIQ Plus next-generation wearable neurostimulation device.

The company's FDA-cleared wearable uses personalized nerve stimulation to treat essential tremor and Parkinson's disease.

The funds from Trinity Capital are expected to advance commercialisation efforts for Cala Health’s device for alleviating ...

Cala Health recently published a post-market surveillance study that demonstrates the long-term efficacy of its wrist-based wearable for people with essential tremor, finding that the device reduced ...

Trinity Capital announced today that it committed $50 million in growth capital to wearable bioelectronic developer Cala ...

Cala is expanding with its second location in the Valley! The renderings showcase the exterior, the entrance, bar area, ...